800-401-4720
Recent Posts
Categories
Archives
Dangerous Drugs
Injuries
Contact Us
Dangerous Drugs and Injuiries Attorneys
Dangerous Drugs and Injuries Lawyers Who We Are What We Do Frequently Asked Questions Contact Us
We Sue Companies That Sell Dangerous Drugs
Nationwide Law Practice click here to be instantly connected to our office Medical and Legal News

Blog Posts in 2009

European Health Agency to Label Gadolinium-Based Contrast Agents as High-, Medium-, or Low-Risk for Causing NSF

The European Medicines Agency (EMEA) issued a press release today, stating that it would begin classifying gadolinium-based contrast agents into three risk categories based on their likelihood of ...
Continue reading "European Health Agency to Label Gadolinium-Based Contrast Agents as High-, Medium-, or Low-Risk for Causing NSF" »

FDA Staff: Omniscan, Magnevist and OptiMARK Gadolinium-Based Contrast Agents Most Likely to Cause NSF

In a recently-prepared FDA document, staff members conclude that Omniscan , Magnevist , and OptiMARK are the gadolinium-based contrast agents with the highest risk of causing Nephrogenic Systemic ...
Continue reading "FDA Staff: Omniscan, Magnevist and OptiMARK Gadolinium-Based Contrast Agents Most Likely to Cause NSF" »

Insurance Coverage for Fleet Phospho-Soda Injuries

A recent settlement likely means more money to pay claims made by people whose kidneys failed after using Fleet Phospho-Soda and Fleet Phospho soda EZ Prep Bowel Cleansing System. Hundreds of people ...
Continue reading "Insurance Coverage for Fleet Phospho-Soda Injuries" »

Movement Toward Consolidation of New Jersey YAZ, Yasmin and Ocella Side Effect Lawsuits

The New Jersey Law Journal has reported that New Jersey YAZ, Yasmin and Ocella lawsuits may be consolidated before a single judge. The New Jersey judiciary is considering a request from Judge Donald ...
Continue reading "Movement Toward Consolidation of New Jersey YAZ, Yasmin and Ocella Side Effect Lawsuits" »

New OptiMARK Label Warns Against Any Use on Patients with Severe Renal Failure

Mallinkrodt Inc., the manufacturer of gadolinium-based contrast agent OptiMARK, announced yesterday that it has submitted a label change that warns against any use of OptiMARK on patients with severe ...
Continue reading "New OptiMARK Label Warns Against Any Use on Patients with Severe Renal Failure" »

UV-A1 Therapy Promising for Nephrogenic Systemic Fibrosis (NSF)

A recent study indicates that UV-A1 phototherapy has promise for reducing symptoms of Nephrogenic Systemic Fibrosis (NSF) . Four patients with NSF were treated with UV-A1. The skin on all four ...
Continue reading "UV-A1 Therapy Promising for Nephrogenic Systemic Fibrosis (NSF)" »

Cancer Drug Gleevec Shows Promise for Treatment of Nephrogenic Systemic Fibrosis (NSF)

A recent clinical trial shows that the cancer drug Gleevec (generic name Imatinib Mesylate) helps lessen the skin symptoms of Nephrogenic Systemic Fibrosis (NSF) . The study was conducted by Dr. ...
Continue reading "Cancer Drug Gleevec Shows Promise for Treatment of Nephrogenic Systemic Fibrosis (NSF)" »

Larger Doses and Repeated Use of Gadolinium-Based Contrast Agents Increase Risk of Nephrogenic Systemic Fibrosis (NSF)

A recently-published study concludes that larger and more frequent use of gadolinium-based contrast agents increases the risk of nephrogenic systemic fibrosis (NSF) . Patients who received higher ...
Continue reading "Larger Doses and Repeated Use of Gadolinium-Based Contrast Agents Increase Risk of Nephrogenic Systemic Fibrosis (NSF)" »

FDA Considered Recommending that GE Gadolinium Contrast Agent Omniscan Never Be Used on Patients with Renal Failure

In May 2007, the FDA ordered all manufacturers of gadolinium-based contrast agents to warn of the risk of Nephrogenic Systemic Fibrosis (NSF) for people with kidney disease. However, the FDA ...
Continue reading "FDA Considered Recommending that GE Gadolinium Contrast Agent Omniscan Never Be Used on Patients with Renal Failure" »

8th Circuit Considers Preemption of Injury Claims Against Generic Drug Manufacturers

Today, the United States Court of Appeals for the Eighth Circuit heard oral argument on whether a failure to warn claim against a generic drug manufacturer is preempted. We discussed this legal issue ...
Continue reading "8th Circuit Considers Preemption of Injury Claims Against Generic Drug Manufacturers" »

FDA to Take a Second Look at Warnings on MRI Drugs

Federal regulators plan to meet in December to review a 2007 decision to issue a blanket warning about the risks of special imaging drugs that are injected as part of MRI scans. The U.S. Food and Drug ...
Continue reading "FDA to Take a Second Look at Warnings on MRI Drugs" »

Multidistrict Litigation (“MDL”) Court Created for YAZ Birth Control Lawsuits

On October 1, 2009, the United States Judicial Panel on Multidistrict Litigation issued an order consolidating lawsuits involving YAZ, Yasmin and Ocella birth control pills . The YAZ multidistrict ...
Continue reading "Multidistrict Litigation (“MDL”) Court Created for YAZ Birth Control Lawsuits" »

Users of Generic Drugs May Have Less Rights When Injured

We often hear that generic drugs are the same as name brand drugs, only they cost less. But not according to drug manufacturers. Drug companies are currently arguing to courts around the country that ...
Continue reading "Users of Generic Drugs May Have Less Rights When Injured" »

Mayo Clinic Study Ignores Risk of Nephrogenic Systemic Fibrosis (NSF) From Gadolinium-Based Contrast Agents

The optimistic sounding conclusion of a recent study on the safety of gadolinium-based contrast agents is misleading to the extent it fails to address the risk of Nephrogenic Systemic Fibrosis (NSF) , ...
Continue reading "Mayo Clinic Study Ignores Risk of Nephrogenic Systemic Fibrosis (NSF) From Gadolinium-Based Contrast Agents" »

The Term "MRI Lawsuit" is Misleading

An internet search for the phrase “MRI lawsuit” will pull up various law-firm and attorney-sponsored websites. The term “MRI lawsuit,” however, is misleading. Magnetic resonance imaging (MRI) itself ...
Continue reading "The Term "MRI Lawsuit" is Misleading" »

Lower Leg Skin Symptoms Can Distinguish Nephrogenic Systemic Fibrosis (NSF) From Other Fibrosing Disorders

Nephrogenic systemic fibrosis (NSF) , also known as nephrogenic fibrosing dermopathy (NFD) , can be difficult to distinguish from other fibrosing skin disorders. However, according to a recent study, ...
Continue reading "Lower Leg Skin Symptoms Can Distinguish Nephrogenic Systemic Fibrosis (NSF) From Other Fibrosing Disorders" »

Skin Symptoms Vary Widely for Nephrogenic Systemic Fibrosis (NSF)

The most common symptom of nephrogenic systemic fibrosis (NSF) is a thickening and hardening of the skin, usually on the lower legs or forearms. However, not all people have the same skin symptoms, ...
Continue reading "Skin Symptoms Vary Widely for Nephrogenic Systemic Fibrosis (NSF)" »

Nephrogenic Systemic Fibrosis: A Frequently Undiagnosed and Misdiagnosed Disease

Because nephrogenic systemic fibrosis (NSF) , also known as nephrogenic fibrosing dermopathy (NFD) , is a new disease, it is often misdiagnosed or goes undiagnosed. Even worse, dialysis patients and ...
Continue reading "Nephrogenic Systemic Fibrosis: A Frequently Undiagnosed and Misdiagnosed Disease" »

Welcome

Welcome to DeCarli Law. We launch this blog with the commitment to provide up-to-date information about the latest warnings and recalls about dangerous drugs, as well as other medical and legal news ...
Continue reading "Welcome " »
Attorney Web Design The information on this website is for general information purposes only. Nothing on this or associated pages, documents, comments, answers, emails, or other communications should be taken as legal advice for any individual case or situation. The information on this website is not intended to create, and receipt or viewing of this information does not constitute, an attorney-client relationship. DeCarli Law only represents individuals pursuant to a signed, written contract.

Address: 50 California Street, Suite 1500 San Francisco CA 94111 Toll Free: 1-800-401-4720 Phone: 1-415-738-6144
Debra DeCarli and Bob DeCarli are licensed by the State Bar of Texas and the State Bar of California.

DeCarli Law represents drug side effects and defective medical devices personal injury clients for claims, lawsuits and settlements in Alabama AL, Alaska AK, Arizona AZ, Arkansas AR, California CA, Colorado CO, Connecticut CT, Delaware DE, Georgia GA, Hawaii HI, Idaho ID, Illinois IL, Kansas KS, Maine ME, Maryland MD, Massachusetts MS, Minnesota MN, Mississippi MS, Montana MT, Nebraska NE, New Hampshire NH, New Jersey NJ, New Mexico NM, New York NY, North Carolina NC, North Dakota ND, Oklahoma OK, Oregon OR, Rhode Island RI, South Carolina SC, South Dakota SD, Tennessee TN, Utah UT, Vermont VT, Virginia VA, Washington WA, Washington D.C, West Virginia WV, Wisconsin WI and Wyoming WY. The attorneys of DeCarli Law are licensed in California and Texas. DeCarli Law's practice includes lawsuits for Propecia side effects, Finasteride lawsuits, Topamax lawsuits, Fosamax lawsuits, Gadolinium lawsuits, NSF lawsuits, Nephrogenic Systemic Fibrosis Lawsuits, YAZ lawsuits, Yasmin lawsuits, Ocella lawsuits, and Zarah lawsuits.